Exicure, Inc. (XCUR) stock
XCURNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.98−0.06 (-5.77%)
Close on Nov 19, 2026Market cap $6.42MP/E –Yield –
Exicure revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Exicure's revenue for the twelve months ending Sep 30, 2026 was $0. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $28.83M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $500.00K | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $28.83M | – |
| FY2021 | Dec 31, 2021 | -$483.00K | -102.9% |
| FY2020 | Dec 31, 2020 | $16.61M | +1181.9% |
| FY2019 | Dec 31, 2019 | $1.30M | +998.3% |
| FY2018 | Dec 31, 2018 | $118.00K | -98.8% |
| FY2017 | Dec 31, 2017 | $9.72M | +838.1% |
| FY2016 | Dec 31, 2016 | $1.04M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0 | – |
| Q2 FY2026 | Jun 30, 2026 | $0 | – |
| Q1 FY2026 | Mar 31, 2026 | $0 | – |
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $0 | – |
| Q3 FY2024 | Sep 30, 2024 | $0 | – |
| Q2 FY2024 | Jun 30, 2024 | $0 | – |
| Q1 FY2024 | Mar 31, 2024 | $500.00K | – |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023 | Jun 30, 2023 | $0 | -100.0% |
| Q1 FY2023 | Mar 31, 2023 | $0 | -100.0% |
| Q4 FY2022 | Dec 31, 2022 | $21.77M | +928.0% |
| Q3 FY2022 | Sep 30, 2022 | $2.02M | – |
| Q2 FY2022 | Jun 30, 2022 | $2.47M | +3027.8% |
| Q1 FY2022 | Mar 31, 2022 | $2.57M | +157.3% |
| Q4 FY2021 | Dec 31, 2021 | $2.12M | +1412.9% |
| Q3 FY2021 | Sep 30, 2021 | -$3.68M | -250.5% |
| Q2 FY2021 | Jun 30, 2021 | $79.00K | -98.4% |
| Q1 FY2021 | Mar 31, 2021 | $997.00K | -89.1% |
| Q4 FY2020 | Dec 31, 2020 | $140.00K | -54.8% |
| Q3 FY2020 | Sep 30, 2020 | $2.44M | +363.6% |
| Q2 FY2020 | Jun 30, 2020 | $4.85M | +1016.8% |
| Q1 FY2020 | Mar 31, 2020 | $9.18M | +36632.0% |
| Q4 FY2019 | Dec 31, 2019 | $310.00K | +5066.7% |
| Q3 FY2019 | Sep 30, 2019 | $527.00K | +824.6% |
| Q2 FY2019 | Jun 30, 2019 | $434.00K | +2184.2% |
| Q1 FY2019 | Mar 31, 2019 | $25.00K | -30.6% |
| Q4 FY2018 | Dec 31, 2018 | $6.00K | -99.7% |
| Q3 FY2018 | Sep 30, 2018 | $57.00K | -91.7% |
| Q2 FY2018 | Jun 30, 2018 | $19.00K | – |
| Q1 FY2018 | Mar 31, 2018 | $36.00K | – |
| Q4 FY2017 | Dec 31, 2017 | $2.10M | – |
| Q4 FY2016 | Dec 31, 2016 | $690.00K | – |
See a number that looks wrong?